

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Ivermectin / Abamectin Liquid Formulation

Supplier's company name, address and phone number

Company name of supplier : MSD

Address : 1-13-12, Kudan-kita, Chiyoda-ku, Tokyo, Japan

Telephone : 03-6272-1099

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION**GHS classification of chemical product**

Acute toxicity (Oral) : Category 4

Acute toxicity (Inhalation) : Category 4

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 2A

Reproductive toxicity : Category 1B

Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)

Specific target organ toxicity - single exposure : Category 3

Specific target organ toxicity - repeated exposure : Category 2 (Central nervous system)

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
14.2	2025/03/24	1210011-00028	2025/02/03
			Date of first issue: 2017/01/10

GHS label elements

Hazard pictograms



Signal word

: Danger

Hazard statements

: H302 + H332 Harmful if swallowed or if inhaled.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
H360D May damage the unborn child.
H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

Prevention:

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapours.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.
P302 + P352 IF ON SKIN: Wash with plenty of water.
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.
P391 Collect spillage.

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
N-Methyl-2-pyrrolidone	872-50-4	20	5-113
Ivermectin	70288-86-7	$\geq 1 - < 2.5$	-
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	1.25	
(dl)-a-Tocopheryl acetate	7695-91-2	< 0.1	9-487

4. FIRST AID MEASURES

- | | |
|-------------------------|--|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| If inhaled | : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention. |
| If swallowed | : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person. |

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
14.2	2025/03/24	1210011-00028	2025/02/03
			Date of first issue: 2017/01/10

Most important symptoms and effects, both acute and delayed	: Harmful if swallowed or if inhaled. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO _x)
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
14.2	2025/03/24	1210011-00028	2025/02/03
			Date of first issue: 2017/01/10

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE**Handling**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Ivermectin / Abamectin Liquid Formulation

Version 14.2 Revision Date: 2025/03/24 SDS Number: 1210011-00028 Date of last issue: 2025/02/03
 Date of first issue: 2017/01/10

Storage

Conditions for safe storage : Keep in properly labelled containers.
 Store locked up.
 Keep tightly closed.
 Keep in a cool, well-ventilated place.
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
 Oxidizing solids
 Oxidizing liquids

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Threshold limit value and permissible exposure limits for each component in the work environment**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	OEL-M	1 ppm 4 mg/m ³	JP OEL JSOH
Further information: Skin absorption				
Ivermectin	70288-86-7	TWA	30 µg/m ³ (OEB 3)	Internal
Further information: Skin				
		Wipe limit	300 µg/100 cm ²	Internal
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	TWA	15 µg/m ³ (OEB 3)	Internal
		Wipe limit	150 µg/100 cm ²	Internal
(dl)-a-Tocopheryl acetate	7695-91-2	TWA	5000 µg/m ³ (OEB 1)	Internal

Biological occupational exposure limits

Components	CAS-No.	Target substance	Biological specimen	Sampling time	Permissible concentration	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy-N-methyl-2-pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
 All engineering controls should be implemented by facility

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
14.2	2025/03/24	1210011-00028	2025/02/03
			Date of first issue: 2017/01/10

design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Combined particulates and organic vapour type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving. Impermeable protective gloves
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	:	liquid
Colour	:	light yellow
Odour	:	characteristic
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Boiling point, initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

Lower explosion limit and upper explosion limit / flammability limit

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : > 100 °C

Decomposition temperature : No data available

pH : No data available

Evaporation rate : No data available

Auto-ignition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : insoluble

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : No data available

Density and / or relative density

Relative density : No data available

Density : 0.91 - 1.00 mg/l

Relative vapour density : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reaction : Can react with strong oxidizing agents.

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

tions
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed or if inhaled.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,031 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 1.84 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:**N-Methyl-2-pyrrolidone:**

Acute oral toxicity : LD50 (Rat): 4,150 mg/kg
Method: OECD Test Guideline 401
Remarks: The test was conducted equivalent or similar to guideline

Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Remarks: The test was conducted according to guideline

Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 402
Remarks: The test was conducted equivalent or similar to guideline

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg
LD50 (Mouse): 10 mg/kg
LDLo (Monkey): 24 mg/kg
Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0.023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg
LD50 (Rabbit): 2,000 mg/kg

(dl)-a-Tocopheryl acetate:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity : LD50 (Rat): > 3,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Causes skin irritation.

Components:**N-Methyl-2-pyrrolidone:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : Skin irritation
Remarks : The test was conducted equivalent or similar to guideline

Ivermectin:

Species : Rabbit

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

Result : No skin irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit
Result : No skin irritation

(dl)-a-Tocopheryl acetate:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**N-Methyl-2-pyrrolidone:**

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days
Method : OECD Test Guideline 405
Remarks : The test was conducted equivalent or similar to guideline

Ivermectin:

Species : Rabbit
Result : Mild eye irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit
Result : Mild eye irritation

(dl)-a-Tocopheryl acetate:

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Test Type : Local lymph node assay (LLNA)
Exposure routes : Skin contact

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

Species	:	Mouse
Method	:	OECD Test Guideline 429
Result	:	negative
Remarks	:	Based on data from similar materials

Ivermectin:

Exposure routes	:	Dermal
Species	:	Humans
Result	:	Does not cause skin sensitisation.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Result	:	Not a skin sensitizer.

(dl)-a-Tocopheryl acetate:

Test Type	:	Draize Test
Exposure routes	:	Skin contact
Species	:	Humans
Result	:	negative

Germ cell mutagenicity

Not classified based on available information.

Components:**N-Methyl-2-pyrrolidone:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative Remarks: The test was conducted according to guideline
-----------------------	---	---

	:	Test Type: In vitro mammalian cell gene mutation test Method: OECD Test Guideline 476 Result: negative Remarks: The test was conducted according to guideline
--	---	--

	:	Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Method: OECD Test Guideline 482 Result: negative Remarks: The test was conducted equivalent or similar to guideline
--	---	--

Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Method: OECD Test Guideline 474 Result: negative
----------------------	---	---

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

Remarks: The test was conducted according to guideline

Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts
Result: negative

Test Type: Mouse Lymphoma
Result: negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

(dl)-a-Tocopheryl acetate:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

Components:**N-Methyl-2-pyrrolidone:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 2 Years
Method	: OECD Test Guideline 451
Result	: negative
Remarks	: The test was conducted according to guideline

Species	: Rat
Application Route	: Inhalation
Exposure time	: 2 Years
Method	: OECD Test Guideline 453
Result	: negative
Remarks	: The test was conducted equivalent or similar to guideline

Ivermectin:

Species	: Rat
Application Route	: Oral
NOAEL	: 1.5 mg/kg body weight
Result	: negative
Remarks	: Based on data from similar materials

Species	: Mouse
Application Route	: Oral
NOAEL	: 2.0 mg/kg body weight
Result	: negative
Remarks	: Based on data from similar materials

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species	: Rat
Application Route	: Oral
Exposure time	: 105 weeks
Result	: negative

Species	: Mouse
Application Route	: Oral
Exposure time	: 93 weeks
Result	: negative

(dl)-a-Tocopheryl acetate:

Species	: Rat
Application Route	: Ingestion
Exposure time	: 104 weeks
Result	: negative

Reproductive toxicity

May damage the unborn child.

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

Components:**N-Methyl-2-pyrrolidone:**

- Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative
Remarks: The test was conducted according to guideline
- Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted according to guideline
- Test Type: Fertility/early embryonic development
Species: Rat
Application Route: inhalation (vapour)
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted equivalent or similar to guideline
- Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted equivalent or similar to guideline
- Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Ivermectin:

- Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.
- Effects on foetal development : Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses
- Test Type: Development

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
14.2	2025/03/24	1210011-00028	2025/02/03
			Date of first issue: 2017/01/10

Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Oral
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight
Result: Fetotoxicity

Effects on foetal development : Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Cleft palate
Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Cleft palate, Teratogenic effects, Reduced embryonic survival
Remarks: Adverse developmental effects were observed

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Teratogenic effects

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

adverse effects on development, based on animal experiments.

(dl)-a-Tocopheryl acetate:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Result: negative

STOT - single exposure

May cause respiratory irritation.

May cause damage to organs (Central nervous system) if swallowed.

Components:**N-Methyl-2-pyrrolidone:**

Assessment : May cause respiratory irritation.

Ivermectin:

Target Organs : Central nervous system
Assessment : Causes damage to organs.

STOT - repeated exposure

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:**Ivermectin:**

Target Organs : Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Exposure routes : Ingestion
Target Organs : Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****N-Methyl-2-pyrrolidone:**

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

Species : Rat, male
NOAEL : 169 mg/kg
LOAEL : 433 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Method : OECD Test Guideline 408
Remarks : The test was conducted according to guideline

Species : Rat
NOAEL : 0.5 mg/l
LOAEL : 1 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 96 Days
Method : OECD Test Guideline 413
Remarks : The test was conducted according to guideline

Species : Rabbit, male
NOAEL : 826 mg/kg
LOAEL : 1,653 mg/kg
Application Route : Skin contact
Exposure time : 20 Days
Method : OECD Test Guideline 410
Remarks : The test was conducted equivalent or similar to guideline

Ivermectin:

Species : Dog
NOAEL : 0.5 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Central nervous system
Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
NOAEL : 1.2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 0.4 mg/kg
LOAEL : 0.8 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : spleen, Bone marrow, Kidney

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
NOAEL : 1.5 mg/kg
Application Route : Oral
Exposure time : 24 Months

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

Target Organs : Central nervous system
Symptoms : Tremors, ataxia

Species : Mouse
NOAEL : 4.0 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Central nervous system
Symptoms : Tremors, ataxia

Species : Dog
NOAEL : 0.25 mg/kg
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Target Organs : Central nervous system
Symptoms : Tremors, weight loss
Remarks : mortality observed

Species : Monkey
NOAEL : 1.0 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Central nervous system

(dl)-a-Tocopheryl acetate:

Species : Rat
NOAEL : 500 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****N-Methyl-2-pyrrolidone:**

Skin contact : Symptoms: Skin irritation

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.

Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
14.2	2025/03/24	1210011-00028	2025/02/03
			Date of first issue: 2017/01/10

Ingestion : Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****N-Methyl-2-pyrrolidone:**

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 1,000 mg/l Exposure time: 24 h Method: DIN 38412 Remarks: The test was conducted according to guideline
Toxicity to algae/aquatic plants	: ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l Exposure time: 72 h EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l Exposure time: 72 h
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 12.5 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: The test was conducted according to guideline
Toxicity to microorganisms	: EC50 (activated sludge): > 600 mg/l Exposure time: 30 min Method: ISO 8192 Remarks: The test was conducted according to guideline

Ivermectin:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l Exposure time: 96 h LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 0.000025 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
14.2	2025/03/24	1210011-00028	2025/02/03
			Date of first issue: 2017/01/10

mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 10,000

M-Factor (Chronic aquatic toxicity) : 10,000

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l
Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l
Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 µg/l
Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Americamysis): 0.022 µg/l
Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 0.34 µg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h

M-Factor (Acute aquatic toxicity) : 10,000

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l
Exposure time: 32 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.03 µg/l
Exposure time: 21 d

NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l
Exposure time: 28 d

M-Factor (Chronic aquatic toxicity) : 10,000

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
14.2	2025/03/24	1210011-00028	2025/02/03
			Date of first issue: 2017/01/10

(dl)-a-Tocopheryl acetate:

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
- Toxicity to fish (Chronic toxicity) : NOEC (Oncorhynchus mykiss (rainbow trout)): 100 mg/l
Exposure time: 28 d
- Toxicity to microorganisms : EC50: > 927 mg/l
Exposure time: 30 min
Method: ISO 8192

Persistence and degradability**Components:****N-Methyl-2-pyrrolidone:**

- Biodegradability : Result: Readily biodegradable.
Biodegradation: 73 %
Exposure time: 28 d
Method: OECD Test Guideline 301C
Remarks: The test was conducted according to guideline

Ivermectin:

- Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 240 d

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

- Stability in water : Hydrolysis: 50 %(< 12 h)

(dl)-a-Tocopheryl acetate:

- Biodegradability : Result: Not readily biodegradable.
Biodegradation: 21.7 - 31 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

Bioaccumulative potential**Components:****N-Methyl-2-pyrrolidone:**

Partition coefficient: n-octanol/water : log Pow: -0.46
Method: OECD Test Guideline 107
Remarks: The test was conducted according to guideline

Ivermectin:

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3.22

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water : log Pow: 4

Mobility in soil**Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Distribution among environmental compartments : log Koc: > 3.6

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), Ivermectin)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

ERG Code : 171

15. REGULATORY INFORMATION**Related Regulations****Fire Service Law**

Group 4, Type 3 petroleum, Water insoluble liquid, (2000 litre), Hazardous rank III

Ivermectin / Abamectin Liquid Formulation

Version 14.2 Revision Date: 2025/03/24 SDS Number: 1210011-00028 Date of last issue: 2025/02/03
Date of first issue: 2017/01/10

Chemical Substance Control Law

Priority Assessment Chemical Substance

Chemical name	Number
N-Methyl-2-pyrrolidone	136

Industrial Safety and Health Law**Harmful Substances Prohibited from Manufacture**

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Substances Subject to be Notified Names

Law Article 57-2 (Ministerial Order Article 34-2 Appended Table 2)

Chemical name	Concentration (%)	Remarks
N-Methyl-2-pyrrolidone	≥ 20 - < 30	-

Substances Subject to be Indicated Names

Law Article 57 (Ministerial Order Article 30 Appended Table 2)

Chemical name	Remarks
N-Methyl-2-pyrrolidone	-

Skin and Eye Damage Substances (ISHL MO Art. 594-2)

Chemical name
N-methyl-2-pyrrolidone

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Deleterious substance

Chemical name	Cabinet Order Number
Abamectin and preparations containing it	4.2

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof**Class I Designated Chemical Substances**

Chemical name	Administration number	Concentration (%)
N-Methyl-2-pyrrolidone	746	20

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Miscellaneous dangerous substances and articles (Article 2 and 3 of rules on shipping and storage of dangerous goods and its Attached Table 1)

Aviation Law

Miscellaneous dangerous substances and articles (Article 194 of The Enforcement Rules of Aviation Law and its Attached Table 1)

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Noxious liquid substance(Category Y)

Pack transportation : Classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

16. OTHER INFORMATION

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH BEI : ACGIH - Biological Exposure Indices (BEI)
JP OEL JSOH : Japan. The Japan Society for Occupational Health. Recommendation of Occupational Exposure Limits

JP OEL JSOH / OEL-M : Occupational Exposure Limit-Mean

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for

Ivermectin / Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2025/02/03
14.2	2025/03/24	1210011-00028	Date of first issue: 2017/01/10

safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN